NCT01591876

Brief Summary

The aim of this study is to evaluate whether a three month intra-dialytic exercise programme improves arterial function.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Nov 2012

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 30, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 4, 2012

Completed
6 months until next milestone

Study Start

First participant enrolled

November 1, 2012

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2013

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2014

Completed
Last Updated

March 1, 2013

Status Verified

February 1, 2013

Enrollment Period

8 months

First QC Date

April 30, 2012

Last Update Submit

February 28, 2013

Conditions

Keywords

exercisekidney diseasevascular functionhaemodialysis

Outcome Measures

Primary Outcomes (1)

  • Brachial artery flow mediated dilatation

    Brachial artery diameter is measured using vascular ultrasound. A cuff similar to that used for blood pressure is then inflated around the forearm for 5 minutes. Following cuff release vascular ultrasound is used to measure arterial dilation in response to reactive hyperaemia. Relative change in diameter provides a measure of endothelial function. Images are recorded over a period of 4-5 minutes post cuff release.

    Baseline and 12 week follow-up

Secondary Outcomes (9)

  • Aortic pulse wave velocity

    Baseline and three month follow-up

  • Maximal aerobic power

    Baseline and three months

  • Timed up-and-go

    Baseline and three month follow-up

  • Sit-to-stand 5

    Baseline and 3 month follow-up

  • Non exercise questionnaire

    Baseline and 3 month follow-up

  • +4 more secondary outcomes

Study Arms (2)

Progressive muscle relaxation

SHAM COMPARATOR

As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.

Other: Progressive Muscle relaxation

Aerobic exercise

ACTIVE COMPARATOR

Intervention -moderate intensity aerobic exercise.

Other: Intradialytic aerobic exercise

Interventions

Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.

Aerobic exercise

This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.

Progressive muscle relaxation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stage 5 CKD patients (GFR \<15 mL/min) receiving maintenance haemodialysis therapy
  • Male or female
  • Aged \>18 years
  • Written informed consent

You may not qualify if:

  • Pregnancy
  • Unstable cardiovascular conditions
  • Recent cerebrovascular event
  • Excess inter-dialytic weight gain
  • Use of corticosteroids, anabolic therapies,
  • Co-morbid catabolic conditions
  • Serum potassium regularly \>6mmol/L
  • Recent pulmonary thromboembolism
  • Psychiatric illness including anxiety, mood and untreated eating disorders
  • Infection or course of antibiotics within one month of study period.
  • Dementia or severe cognitive impairment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Monklands Hospital

Airdrie, ML6 0JS, United Kingdom

RECRUITING

MeSH Terms

Conditions

Renal Insufficiency, ChronicMotor ActivityKidney Diseases

Interventions

Autogenic Training

Condition Hierarchy (Ancestors)

Renal InsufficiencyUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBehavior

Intervention Hierarchy (Ancestors)

HypnosisMind-Body TherapiesComplementary TherapiesTherapeuticsPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Tom Mercer, Professor

    Queen Margaret University

    STUDY DIRECTOR

Central Study Contacts

Sean Prescott, MSc

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Research Student

Study Record Dates

First Submitted

April 30, 2012

First Posted

May 4, 2012

Study Start

November 1, 2012

Primary Completion

July 1, 2013

Study Completion

February 1, 2014

Last Updated

March 1, 2013

Record last verified: 2013-02

Locations